26 jul: GRAIN HIGHLIGHTS: Top Stories of the Day
26 jul: UPDATE: Prologis Posts Modest Second-Quarter Profit
26-07-2012 22:51:00

Amgen 2nd-Quarter Profit Rises 8.2%; 2012 Outlook Raised

Relateret indhold

By Tess Stynes

Amgen Inc.'s (AMGN) second-quarter earnings rose 8.2% as weaker sales of the biopharmaceutical company's anemia drugs were offset by growth of other treatments.

Shares rose 4.7% to $83 in after-hours trading Thursday as adjusted earnings and revenue beat expectations and the company raised its 2012 outlook. Through the close, the stock was up about 23% this year.

For the year, the company raised its per-share earnings estimate to a range of $6.20 to $6.35 on revenue of $16.9 billion to $17.2 billion, from its prior estimates for $5.90 to $6.15 and $16.1 billion to $16.5 billion.

Amgen has been pursuing deals to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed a $1.16 billion acquisition of Micromet Inc., a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.27 billion, or $1.61 a share, up from $1.17 billion, or $1.25 a share, a year earlier. Excluding acquisition-related charges, stock-compensation expenses and other items, earnings were up at $1.83 from $1.37.

Revenue increased 13% to $4.48 billion, including 8% growth in product sales.

Analysts polled by Thomson Reuters most recently projected earnings of $1.54 a share on revenue of $4.08 billion.

Combined sales of Neulasta and Neupogen, which are used to ward off infections in patients undergoing cancer treatment, grew 2% mainly on an increase in U.S. average selling prices. Enbrel sales jumped 11%.

However, sales of anti-anemia drugs Aranesp and Epogen were down about 8% and 3%, respectively.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Second-quarter sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, saw sales increase 17% from the first quarter. Sales of Prolia, for osteoporosis in women, climbed 36% quarter to quarter.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 16:51 ET (20:51 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aarhus Elite får kæmpeunderskud efter sportslig fiasko

23-09-2014 16:36:34
Ikke alene har børsnoterede Aarhus Elite måttet lide den tort at se sit fodboldhold AGF rykke ned i næstbedste række i 2014. Selskabets regnskab for året 2013/1..

Vestas-konkurrent venter at installere op mod 4 gigawatt i år

23-09-2014 13:37:11
Den tyske vindmølleproducent Enercon, som sidste år rangerede som verdens tredjestørste vindmølleproducent og blandt andet tegnede sig knap halvdelen af install..

Vestas-rival lancerer større møller

23-09-2014 09:20:53
Når vindmøllegiganterne Vestas og Siemens de senere år har lanceret nye møller, har der primært været tale om videreudviklinger af tidligere produkter. Den opsk..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas-rival lancerer større møller
2
Europa/aktier: Varsel om luk af skattefidus sender aktier ned
3
Aktier/tendens: Ny rekordjagt i sigte for C20 Cap
4
Vestas: USA pusler med forlængelse af vitale støtteordninger
5
Rohde blæser til kamp mod fradrag, afdragsfrihed og skattestop

Relaterede aktiekurser

Amgen Inc 140,68 -1,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen
Køb

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. september 2014 22:25:05
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140919.1 - EUROWEB2 - 2014-09-23 22:25:05 - 2014-09-23 22:25:05 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x